CN113166103A - Egfr抑制剂及其应用 - Google Patents

Egfr抑制剂及其应用 Download PDF

Info

Publication number
CN113166103A
CN113166103A CN202080006242.5A CN202080006242A CN113166103A CN 113166103 A CN113166103 A CN 113166103A CN 202080006242 A CN202080006242 A CN 202080006242A CN 113166103 A CN113166103 A CN 113166103A
Authority
CN
China
Prior art keywords
compound
reaction
amino
group
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080006242.5A
Other languages
English (en)
Other versions
CN113166103B (zh
Inventor
刘磊
谷晓辉
刘扬
诸舜伟
薛黎婷
于晓虹
张国宝
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN113166103A publication Critical patent/CN113166103A/zh
Application granted granted Critical
Publication of CN113166103B publication Critical patent/CN113166103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及作为第四代(T790M/C797S突变)EGFR激酶抑制剂及其医药用途，具体公开了式(I)所示化合物或其药学上可接受的盐。本发明化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。
Figure DDA0003068611530000011

Description

PCT国内申请，说明书已公开。

Claims (37)

  1. PCT国内申请，权利要求书已公开。
CN202080006242.5A 2019-04-26 2020-04-24 Egfr抑制剂及其应用 Active CN113166103B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910345963 2019-04-26
CN2019103459638 2019-04-26
CN2019108105076 2019-08-29
CN201910810507 2019-08-29
PCT/CN2020/086871 WO2020216371A1 (zh) 2019-04-26 2020-04-24 Egfr抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN113166103A true CN113166103A (zh) 2021-07-23
CN113166103B CN113166103B (zh) 2022-12-16

Family

ID=72941485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080006242.5A Active CN113166103B (zh) 2019-04-26 2020-04-24 Egfr抑制剂及其应用

Country Status (2)

Country Link
CN (1) CN113166103B (zh)
WO (1) WO2020216371A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111410667A (zh) * 2019-01-08 2020-07-14 武汉宇科源医药生物科技有限公司 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途
CN115536699A (zh) * 2022-12-01 2022-12-30 北京鑫开元医药科技有限公司 一种新型EGFR-TKIs、制备方法、药物组合物及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230026840A1 (en) * 2019-11-21 2023-01-26 Tyk Medicines, Inc. Compound used as egfr kinase inhibitor and use thereof
CN114728932A (zh) * 2019-11-29 2022-07-08 江苏先声药业有限公司 作为egfr激酶抑制剂的多芳基化合物
CN113717156B (zh) * 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
WO2021244502A1 (zh) * 2020-06-03 2021-12-09 江苏先声药业有限公司 多芳基化合物及应用
US20230212147A1 (en) * 2020-06-08 2023-07-06 Hongyun Biotech Co., Ltd. Alkenyl pyrimidine compound, preparation method therefor, and application thereof
CN116438172A (zh) * 2020-11-13 2023-07-14 南京红云生物科技有限公司 Hpk1激酶调节剂、其制备方法与应用
US20240165243A1 (en) * 2021-02-10 2024-05-23 Beigene Switzerland Gmbh Egfr degraders and methods of use
EP4286376A1 (en) * 2021-04-01 2023-12-06 Therapex Co., Ltd. Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same
TW202313034A (zh) * 2021-08-19 2023-04-01 大陸商貝達藥業股份有限公司 Egfr抑制劑的鹽、晶型及其組合物和應用
TW202317117A (zh) * 2021-10-14 2023-05-01 大陸商齊魯製藥有限公司 一種三環化合物的用途
CN118076614A (zh) * 2021-10-14 2024-05-24 齐鲁制药有限公司 一种egfr抑制剂的多晶型
CN116063307A (zh) * 2021-10-29 2023-05-05 中国药科大学 Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用
TW202339768A (zh) * 2022-01-18 2023-10-16 英屬開曼群島商百濟神州有限公司 藉由軛合ｅｇｆｒ抑制劑與ｅ３連接酶配體降解ｅｇｆｒ及其使用方法
CN115073364B (zh) * 2022-06-20 2024-04-05 上海毕得医药科技股份有限公司 一种6-硝基吡啶-3-醇的制备方法
WO2024046405A1 (zh) * 2022-09-01 2024-03-07 齐鲁制药有限公司 一种egfr激酶抑制剂的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN106699810A (zh) * 2015-11-17 2017-05-24 清华大学 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
WO2017086829A1 (ru) * 2015-11-19 2017-05-26 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетаты замещенных n4-[2-(диметилфосфиноил) фенил]-n2-(2-метокси-4-пиперидин-1-илфенил)-5-хлорпиримидин-2,4-диаминов в качестве модуляторов alk и egfr, предназначенных для лечения рака
WO2017086832A1 (ru) * 2015-11-19 2017-05-26 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") Замещенные n2-(4-амино-2-метокси-фенил)- n4-[2-(диметилфосфиноил)-фенил]- 5-хлор-пиримидин-2,4-диамины в качестве модуляторов alk и egfr, предназначенные для лечения рака
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN106699810A (zh) * 2015-11-17 2017-05-24 清华大学 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
WO2017086829A1 (ru) * 2015-11-19 2017-05-26 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетаты замещенных n4-[2-(диметилфосфиноил) фенил]-n2-(2-метокси-4-пиперидин-1-илфенил)-5-хлорпиримидин-2,4-диаминов в качестве модуляторов alk и egfr, предназначенных для лечения рака
WO2017086832A1 (ru) * 2015-11-19 2017-05-26 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") Замещенные n2-(4-амино-2-метокси-фенил)- n4-[2-(диметилфосфиноил)-фенил]- 5-хлор-пиримидин-2,4-диамины в качестве модуляторов alk и egfr, предназначенные для лечения рака
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.B.西尔弗曼: "《有机药物化学》", 31 January 2008 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111410667A (zh) * 2019-01-08 2020-07-14 武汉宇科源医药生物科技有限公司 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途
CN115536699A (zh) * 2022-12-01 2022-12-30 北京鑫开元医药科技有限公司 一种新型EGFR-TKIs、制备方法、药物组合物及其应用

Also Published As

Publication number Publication date
CN113166103B (zh) 2022-12-16
WO2020216371A1 (zh) 2020-10-29

Similar Documents

Publication Publication Date Title
CN113166103B (zh) Egfr抑制剂及其应用
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN107531690B (zh) 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
JP6847844B2 (ja) 治療用ピリダジン化合物およびその使用
CN107011348B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2021031952A1 (zh) 氧代六元环并嘧啶类化合物，其制法与医药上的用途
WO2020177629A1 (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN113396147A (zh) 芳香杂环类衍生物调节剂、其制备方法和应用
CN112368283A (zh) 含二并环类衍生物抑制剂、其制备方法和应用
CN108349996B (zh) 三环pi3k抑制剂化合物及其使用方法
CN112538072A (zh) 新型氨基嘧啶类egfr抑制剂
KR20220166789A (ko) 거대고리 화합물 및 이의 용도
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3992197A1 (en) Nitrogen-containing polycyclic fused ring compounds, and pharmaceutical composition thereof, preparation method therefor and application thereof
CN117062818A (zh) 新型sos1抑制剂及其制备方法和应用
JP2022534063A (ja) インドール誘導体含有阻害剤、そのための調製方法及びその用途
WO2022161461A1 (zh) Sos1抑制剂及其制备方法和应用
TW202321219A (zh) 雜環衍生物及其組合物和藥學上的應用
KR20230136766A (ko) 질소 함유 다환 축합 고리계 화합물, 이의 약학 조성물,제조 방법 및 용도
TW201927787A (zh) 吡咯並三嗪化合物及抑制ｔａｍ激酶之方法
CN113072551A (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
CN112771032B (zh) 作为第四代egfr抑制剂的嘧啶吡唑类化合物
CN113166141A (zh) 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant